Results from clinical trial with Diamyd[®] in children at high risk for type 1 diabetes
Results from the investigator initiated prevention trial DiAPREV-IT 2, where 26 healthy children at high risk for type 1 diabetes have been treated with two subcutaneous injections of Diamyd[®] or placebo, showed that over the course of two years, one individual in the Diamyd[®] arm and two individuals in the placebo arm were diagnosed. No safety concerns were raised and the safety profile was comparable between the active arm and the placebo arm.The trial, led by Associate Professor Helena Elding Larsson, Lund University, was originally designed to follow 80 children over the course of
